Personalis (NASDAQ:PSNL) had its price objective dropped by research analysts at Needham & Company LLC from $38.00 to $33.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price points to a potential upside of 69.58% from the stock’s current price.
Several other research analysts have also recently issued reports on PSNL. Truist started coverage on Personalis in a research report on Wednesday, January 27th. They set a “buy” rating and a $50.00 price objective for the company. Morgan Stanley cut their price target on shares of Personalis from $38.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, May 7th. HC Wainwright lifted their target price on shares of Personalis from $30.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, January 13th. Finally, Oppenheimer upgraded shares of Personalis from a “market perform” rating to an “outperform” rating and set a $28.00 price target for the company in a report on Thursday, May 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $37.60.
Shares of NASDAQ PSNL opened at $19.46 on Wednesday. Personalis has a 12-month low of $10.02 and a 12-month high of $53.46. The stock has a market cap of $854.45 million, a P/E ratio of -18.36 and a beta of 1.71. The business’s fifty day simple moving average is $23.08 and its 200-day simple moving average is $31.28.
In other Personalis news, insider Richard Chen sold 40,000 shares of Personalis stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $25.69, for a total transaction of $1,027,600.00. Following the completion of the sale, the insider now owns 62,094 shares of the company’s stock, valued at approximately $1,595,194.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Aaron Tachibana sold 3,022 shares of the business’s stock in a transaction on Tuesday, March 2nd. The shares were sold at an average price of $32.60, for a total transaction of $98,517.20. Following the transaction, the chief financial officer now owns 170,269 shares in the company, valued at $5,550,769.40. The disclosure for this sale can be found here. Insiders sold a total of 46,943 shares of company stock worth $1,232,951 in the last quarter. 8.20% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in PSNL. Penserra Capital Management LLC lifted its position in shares of Personalis by 171.2% during the 4th quarter. Penserra Capital Management LLC now owns 895 shares of the company’s stock worth $32,000 after purchasing an additional 565 shares during the last quarter. Banque Cantonale Vaudoise grew its position in shares of Personalis by 66.7% during the 1st quarter. Banque Cantonale Vaudoise now owns 1,500 shares of the company’s stock worth $37,000 after buying an additional 600 shares during the period. NEXT Financial Group Inc bought a new stake in shares of Personalis during the 4th quarter valued at $25,000. AdvisorNet Financial Inc bought a new position in Personalis during the 4th quarter worth approximately $27,000. Finally, Rhumbline Advisers boosted its position in shares of Personalis by 3.3% during the first quarter. Rhumbline Advisers now owns 25,554 shares of the company’s stock worth $629,000 after purchasing an additional 818 shares in the last quarter. 65.46% of the stock is currently owned by institutional investors.
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Recommended Story: Why Invest in High-Yield Dividend Stocks?
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.